## CAH: Cardinal Health, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.1% below STRENGTH zone (3.0-6.0%); PEG 1.89 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($190.56)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. Natixis Cuts Stock Position in Cardinal Health, Inc. $CAH**
- Source: MarketBeat | 20251209T130811 | Somewhat-Bullish | Relevance: 100%
-  Natixis reduced its stake in Cardinal Health, Inc. (NYSE:CAH) by 45.8% in the second quarter, selling 72,854 shares but still owning 86,051 shares valued at $14.46 million. Despite this, Cardinal Health reported strong Q2 earnings, beating analyst estimates with $2.55 EPS and setting positive FY2026 guidance, leading to a consensus "Moderate Buy" rating from analysts. Other institutional investors, however, increased their positions in the company, highlighting mixed sentiment among institutional holders.

**2. Is Cardinal Health Still Attractively Priced After Its Huge 2025 Run And DCF Upside?**
- Source: Simply Wall Street | 20251211T160826 | Bullish | Relevance: 99%
-  Cardinal Health (NYSE:CAH) has seen significant stock appreciation in 2025 but, according to a Discounted Cash Flow (DCF) analysis, its shares are still trading at a 57.1% discount to their estimated fair value. While its Price to Earnings (PE) ratio of 29.5x is slightly above the industry average, it aligns closely with Simply Wall St's proprietary "Fair Ratio" of 29.1x, suggesting the stock is priced appropriately based on current earnings. The article encourages investors to use "Narratives" for a more nuanced valuation, considering differing perspectives on future revenue and risks.

**3. Barclays Initiates Coverage on Cardinal Health (CAH) with Overweight Rating**
- Source: Finviz | 20251211T130802 | Bullish | Relevance: 99%
-  Barclays has initiated coverage on Cardinal Health (CAH) with an Overweight rating and a $243 price target, citing its strong performance and shift towards higher-margin healthcare areas like specialty pharmaceuticals. The company's recent acquisition of Solaris Health further expands its multi-specialty MSO platform, contributing to a 22% increase in total Q1 2026 revenue. The firm is most optimistic about drug distributors within the healthcare technology and distribution sector.

**4. Investors in Cardinal Health (NYSE:CAH) have seen massive returns of 315% over the past five years**
- Source: Yahoo Finance | 20251211T080000 | Bullish | Relevance: 99%
- Cardinal Health shareholders have experienced impressive returns, with a 265% increase in stock price over five years and a total shareholder return (TSR) of 315% when accounting for dividends. The company transitioned from a loss to profitability during this period, indicating strong underlying business performance. Recent performance shows a 71% TSR over the last twelve months, surpassing the annualized return of the previous half-decade.

**5. Is Cardinal Health Stock Outperforming the Nasdaq?**
- Source: inkl | 20251210T130730 | Bullish | Relevance: 99%
- Cardinal Health (CAH) has significantly outperformed the Nasdaq Composite ($NASX) over the past three months, six months, and 52 weeks, driven by strong sentiment and solid earnings. The healthcare services and products firm reported a 22% year-over-year revenue increase and a 36% non-GAAP EPS increase in Q1 fiscal 2026, leading to a raised outlook. Analysts maintain a "Strong Buy" rating with an expected upside.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $243 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 11 ($0.00M) |
| Sells | 5 ($0.41M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Blackrock Inc.: 13.2% (+3.0%)
- Vanguard Group Inc: 13.0% (+0.8%)
- State Street Corpora: 5.2% (-3.0%)
- Geode Capital Manage: 2.7% (+1.5%)
- Wellington Managemen: 2.4% (+153.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.89 elevated, pricing in significant growth expectations. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $47.1B |
| Beta | 0.64 |
| 52W Range | $114.60 - $214.93 |
| Short Interest | 3.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.89 |
| Forward P/E | 17.9 |
| Current P/E | 20.2 |
| YoY Growth | 12.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -5.6% to -2.1% (+3.5% in 5 days), confirming momentum buildup. Below STRENGTH zone by 5.1pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.26x) but short-term weakness (below SMA20). MACD histogram bearish (-2.81), momentum weakening. RSI neutral at 51.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.07% (CS: 16) | Weak |
| RSI_14 | 50.6 | Neutral |
| MACD Histogram | -2.81 | Bearish |
| vs SMA20 | 0.966x | Below |
| vs SMA50 | 1.073x | Above |
| vs SMA200 | 1.260x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $198.32
- **Stop Loss:** $190.56 (3.9% risk)
- **Target:** $206.08 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 177
- **Position Value:** $35,102.64
- **Portfolio %:** 35.10%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-01-29 (Est: $2.30)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.17 | $2.55 | +17.3% |
| 2025Q2 | $2.03 | $2.08 | +2.4% |
| 2025Q1 | $2.15 | $2.35 | +9.4% |
| 2024Q4 | $1.76 | $1.93 | +9.4% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*